Literature DB >> 12953623

The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis.

Alan A Baumeister1, Mike F Hawkins, Sarah M Uzelac.   

Abstract

For five decades it has been generally accepted that reserpine, an antihypertensive and antipsychotic drug, causes depression. The discovery that reserpine depletes brain monoamines was an important factor in the development of the monoamine hypothesis of depression, and it continues to be widely cited in support of this hypothesis. The present paper argues that, contrary to prevailing belief, reserpine is not depressogenic. The reason for perpetuation of this myth is reluctance to discard the monoamine hypothesis. This hypothesis ushered the modern biochemical paradigm into psychiatry and is still of great importance. It serves as a heuristic to guide research, it enhances psychiatry's prestige, and it helps to validate and promote drug therapy for depression and other mental disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953623     DOI: 10.1076/jhin.12.2.207.15535

Source DB:  PubMed          Journal:  J Hist Neurosci        ISSN: 0964-704X            Impact factor:   0.529


  23 in total

1.  Medical models and metaphors for depression.

Authors:  S B Patten
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-16       Impact factor: 6.892

2.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

Review 3.  The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse.

Authors:  Jacob P R Jacobsen; Ivan O Medvedev; Marc G Caron
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

Review 4.  Pain and depression comorbidity: a preclinical perspective.

Authors:  Jun-Xu Li
Journal:  Behav Brain Res       Date:  2014-05-02       Impact factor: 3.332

5.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 6.  Rauwolfia in the Treatment of Hypertension.

Authors:  Douglas Lobay
Journal:  Integr Med (Encinitas)       Date:  2015-06

Review 7.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

8.  General medical with depression drugs associated.

Authors:  Donald Rogers; Ronald Pies
Journal:  Psychiatry (Edgmont)       Date:  2008-12

Review 9.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

10.  Antidepressant and Anxiolytic-Like Effects of the Stem Bark Extract of Fraxinus rhynchophylla Hance and Its Components in a Mouse Model of Depressive-Like Disorder Induced by Reserpine Administration.

Authors:  Yu Ri Kim; Bo-Kyung Park; Chang-Seob Seo; No Soo Kim; Mi Young Lee
Journal:  Front Behav Neurosci       Date:  2021-06-17       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.